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Mycobacterium kansasii is the second most common cause of slowly growing non-
tuberculous mycobacteria diseases in China. The aim of the present study was to
analyze M. kansasii subtypes isolated from patients in China, and to explore the
antimicrobial susceptibility of the differentiation among these diverse subtypes. A total
of 78 M. kansasii strains from 16 provinces of China were enrolled in this study.
Amikacin (AMK) was the most highly active against M. kansasii strains, and only 4
isolates (5.1%) exhibited in vitro resistance to AMK. The percentage of levofloxacin
(LFX) resistant strains among the 78 M. kansasii isolates was 39.7% (31/78), which was
significantly higher than that of moxifloxacin (16.7%, P = 0.001) and gatifloxacin (19.2%,
P = 0.005). By using PCR-restriction fragment analysis of the hsp65 gene (PRA), all the
isolates were classified as four different subtypes. Of these four subtypes, M. kansasii
subtype I was the most frequent genotype in China, accounting for 71.8% (56/78) of
M. kansasii isolates. Resistance to clarithromycin (CLA) was noted in 26.8% (15/56)
of subtype I isolates, which was significant higher than that of other subtypes (4.5%,
P = 0.031). DNA sequencing revealed that the presence of mutations in 23S rRNA was
associated with 56.2% (9/16) of CLA-resistant M. kansasii isolates. In conclusion, our
data demonstrate that AMK is the most active agent against M. kansasii in vitro, while
the high proportion of CLA resistance is noted in M. kansasii isolates. In addition, the
predominant subtype I is associated with CLA resistance in China.
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INTRODUCTION
Nontuberculous mycobacteria (NTM) are a large, diverse group of environment organisms that
are ubiquitous in the soil, water, animals, human, and food (Griffith et al., 2007; Prevots and
Marras, 2015). Despite of low pathogenicity to humans, NTM can cause a wide array of clinical
illness, especially in human immune-deficiency virus (HIV) infected patients or those with severely
compromised immune systems (Prevots and Marras, 2015). In recent years, increasing attention
has been paid to disease caused by NTM because of its more prevalent incidence globally (Hoefsloot
et al., 2013; Russell et al., 2014).
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Only behind Mycobacterium avium complex, Mycobacterium
kansasii is the second most common cause of NTM diseases
in South American and some European countries (Hoefsloot
et al., 2013). In addition to the most frequent pulmonary disease,
M. kansasii is a contributor to various clinical manifestations,
including extrapulmonary and disseminated diseases in patients
with immunodeficiencies (Campo and Campo, 1997; Pintado
et al., 1999). Previous epidemiological studies have demonstrated
that patients with chronic lung disease, previous mycobacterial
disease, malignancy, and alcoholism are at high risk for
M. kansasii infection (Guay, 1996). M. kansasii is often
recovered from tap water, and occasionally from natural water
(McSwiggan and Collins, 1974; Steadham, 1980; Taillard et al.,
2003). Due to wide exposure to the bacterium, human-to-
human transmission of M. kansasii is traditionally thought
to be uncommon (Ricketts et al., 2014). However, a recent
report from Ricketts et al. (2014) observed the potential
transmission of M. kansasii given the ideal circumstances,
providing important insights for public health concern regarding
M. kansasii.
PCR-restriction fragment analysis of the hsp65 gene (PRA) is
a powerful technique of differentiating heterogeneous subtypes
of M. kansasii (Telenti et al., 1993; Santin et al., 2004). To
date, seven subtypes (I-VII) have been identified based on
the PCR-RFLP profiles (Picardeau et al., 1997; Richter et al.,
1999; Santin et al., 2004). Of these seven subtypes, subtype I
represents the most frequent isolates contributing to human
disease (Taillard et al., 2003), and subtype II is likely to be
observed in HIV-infected patients, indicating that it may act
as an opportunistic agent (Witzig et al., 1995). In contrast, the
other five subtypes are generally isolated from environmental
samples rather than human specimens (Alcaide et al., 1999).
The niche heterogeneity indicates that there may be diverse
pathogenicity and biological features among the M. kansasii
subtypes (Santin et al., 2004). Considering drug susceptibility is
an important indicator for predicting the clinical outcome of
patients infected with M. kansasii, it is meaningful to investigate
the assumed difference in drug susceptibility profiles of these
seven subtypes. Unfortunately, limited data is known regarding
this issue. The aim of the present study was to analyze M. kansasii
subtypes isolated from patients in China, and to explore the
antimicrobial susceptibility of the differentiation among these
diverse subtypes.
MATERIALS AND METHODS
Ethics Statement
The protocols applied in this study were approved by the Ethics
Committee of Beijing Hospital. The M. kansasii isolates obtained
from patients were anonymized, processed using strain number
only and were not associated with any identifying details.
M. kansasii Isolates
The strains used in this study were collected from national
surveillance of drug resistant tuberculosis from 2008 to 2015
(Zhao et al., 2012; Zhang et al., 2015). All the positive
mycobacterial cultures were transferred to National Tuberculosis
Reference Laboratory for species identification. Conventional
species identification was performed with the Löwenstein–Jensen
(L–J) medium containing paranitrobenzoic acid (PNB) and
thiophen-2-carboxylic acid hydrazide (TCH) (Zhang et al., 2015).
The isolates identified as NTM by biochemical method were
further divided into species level with sequencing of multiple
genes, including 16S rRNA, 65-kD heat shock protein (hsp65),
RNA polymerase subunit beta (rpoB), and 16S-23S rRNA internal
transcribed spacer (ITS) sequence (Zhang et al., 2015). Briefly,
the crude genomic DNA was extracted from colonies harvested
from L–J medium according to previous report. The 50 µl
amplification mixtures were prepared as follow: 25 µl 2×
GoldStar MasterMix (CWBio, Beijing, China), 0.2 µM of each
primer set and 5 µl of genomic DNA. PCR program was
performed for 35 cycles (94◦C for 60 s, 60◦C for 60 s, and
72◦C for 60 s). The amplicons were sent to Tsingke Company
(Beijing, China) for sequencing service. DNA sequence analysis
was performed by alignment with the homologous sequences
of the reference mycobacterial strains using multiple sequence
alignments1. A total of 78 M. kansasii isolates confirmed by
molecular method were enrolled for further drug susceptibility
testing and PRA identification.
Minimal Inhibitory Concentration (MIC)
Antimicrobial susceptibility testing was performed following
the guidelines by the Clinical and Laboratory Standards
Institute [CLSI], 2011. Cation-adjusted Mueller-Hinton
broth (CAMHB) plus 5% OADC (oleic acid- albumin-
dextrose-catalase) was used for broth microdilution testing.
A total of twenty antimicrobial agents were selected for
MIC determination, including isoniazid (INH), streptomycin
(STR), clarithromycin (CLA), amikacin (AMK), rifampicin
(RIF), rifabutin (RFB), ethambutol (EMB), linezolid (LZD),
moxifloxacin (MOX), levofloxacin (LFX), gatifloxacin (GAT),
sulfamethoxazole (SUL), azithromycin (AZM), capreomycin
(CAP), tigecycline (TGC), meropenem (MER), minocyline
(MIN), cefoxitin (CFX), tobramycin (TOB) and clofazimine
(CLO). The concentrations tested ranged from 0.0625 to
128 µg/ml. The breakpoints of antimicrobial agents were
recommended by the CLSI:CLA, > 16 µg/ml;RFB, > 1
µg/ml;AMK, > 32 µg/ml;EMB, > 4 µg/ml;LZD, > 16 µg/ml;
MOX, > 2 µg/mL;RFB, > 2 µg/ml; and SUL, > 32 µg/ml
(Clinical and Laboratory Standards Institute [CLSI], 2011). In
addition, the breakpoint of levofloxacin was referenced from a
previous report, defined as >2 µg/ml (Hombach et al., 2013).
For gatifloxacin, the temporary breakpoint was set as > 2 µg/ml,
which was also used as breakpoint values of ciprofloxacin,
levofloxacin and moxifloxacin. The reference M. kansasii strain
(ATCC12478) was enrolled in each batch for quality control
purpose.
PRA Identification
The PRA identification was performed as previously described
(Telenti et al., 1993). The 441-bp fragment of the hsp65 gene was
1http://www.ncbi.nlm.nih.gov/BLAST
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FIGURE 1 | Distribution of Mycobacterium kansasii isolates in this study.
amplified from genomic DNA with primers Tb11 and Tb12. The
PCR product was subjected to restriction enzyme analysis with
BstE II and Hae III. The restriction fragments were identified by
electrophoresis on a 3% of agarose gel. The patterns of PRA were
evaluated at the SwissPRAsite2.
DNA Sequencing
The region corresponding to domain V of the 23S ribosomal
RNA (23S rRNA) gene was amplified with primer F1
(5′-GCAAGGGTGAAGCGGAGAA-3′) and primer R1 (5′-
GCACTTACACTCGCCACCTGA-3′). The amplicons were
analyzed by DNA sequencing. The DNA sequences were aligned
with the homologous sequences of the reference M. kansasii
strain (ATCC12478) with multiple sequence alignments3.
2http://app.chuv.ch/prasite/index.html
3http://www.ncbi.nlm.nih.gov/BLAST
Statistical Analysis
The differences in proportions of drug resistance between
different M. kansasii subtypes were evaluated with chi-square
test or Fisher’s exact test. Statistical analysis was performed using
SPSS, version 15.0 (SPSS Inc., Chicago, IL, USA). The difference
was considered to be statistically significant when P < 0.05.
RESULTS
Drug Susceptibility Testing
A total of 78 M. kansasii strains from 13 provinces of China
were enrolled for further drug susceptibility testing in this study
(Figure 1). The range of MICs of each antimicrobial agent for
M. kansasii isolates is detailed qualitatively in Table 1. AMK
was the most highly active against M. kansasii strains, and
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TABLE 1 | In vitro susceptibility of Mycobacterium kansasii isolates
against 20 antimicrobial agents enrolled in this study.
Antimicrobial
agent
MIC range
(µg/ml)
MIC50
(µg/ml)
MIC90
(µg/ml)
No. of resistant
strains (%)a
CLA 0.063–128 0.25 128 16 (20.5)
AMK 0.5–64 4 32 4 (5.1)
RIF 0.063–128 2 32 44 (56.4)
RFB 0.063–64 0.25 32 27 (34.6)
EMB 0.13–64 2 32 16 (20.5)
LZD 0.13–128 4 128 25 (32.1)
MOX 0.063–16 0.25 4 13 (16.7)
LFX 0.063–32 2 16 31 (39.7)
GAT 0.063–16 0.5 4 15 (19.2)
SUL 0.25–128 4 128 13 (16.7)
AZM 0.5–128 16 32 –
CAP 0.063–128 1 32 –
TGC 0.25–128 64 128 –
MER 0.25–128 128 128 –
MIN 0.25–128 4 32 –
STR 1–128 8 128 –
CFX 2–128 128 128 –
TOB 0.5–128 8 64 –
CLO 0.06–128 1 64 –
INH 1–64 4 64 –
a INH, isoniazid; STR, streptomycin; CLA, clarithromycin; AMK, amikacin; RIF,
rifampicin; RFB, rifabutin; EMB, ethambutol; LZD, linezolid; MOX, moxifloxacin;
LFX, levofloxacin; GAT, gatifloxacin; SUL, sulfamethoxazole; AZM, azithromycin;
CAP, capreomycin; TGC, tigecycline; MER, meropenem; MIN, minocycline; CFX,
cefoxitin; TOB, tobramycin; CLO, clofazimine.
bMIC50 represents the concentration required to inhibit the growth of 50% of the
strains; MIC90 represents the concentration required to inhibit the growth of 90%
of the strains.
only 4 isolates (5.1%) exhibited in vitro resistance to AMK.
Fluoroquinolone susceptibility was variable among MOX, LFX
and GAT, the MIC50s and MIC90s of which were 0.25 µg/ml
and 4 µg/ml for MOX, 2 µg/ml and 16 µg/ml for LFX, and
0.5 µg/ml and 4 µg/ml for GAT, respectively. When using
the CLSI breakpoints, the percentage of LFX-resistant strains
among the 78 M. kansasii isolates was 39.7% (31/78), which
was significantly higher than that of MOX (16.7%, P = 0.001)
and GAT (19.2%, P = 0.005). The levels of cross-resistance
among fluoroquinolones are presented in Figure 2. Of the 31
isolates that were resistant to LFX, 13 (41.9%) and 15 (48.4%)
isolates exhibited resistance to MOX and GAT, respectively. In
addition, the isolates resistant to MOX and/or GAT were all
resistant to LFX. For rifamycins, there were 44 (56.4%) and 27
(34.6%) isolates resistant to RIF and RFB, respectively. Statistical
analysis revealed that the percentage of RFB-resistant isolates was
significantly lower than that of RIF (P = 0.006).
We further analyzed the drug susceptibility of M. kansasii
isolates against antimicrobial agents without the breakpoint
values. Out of these ten drugs, CAP showed the most activity
against M. kansasii, with a MIC50 of 1 µg/ml and an MIC90 of 32
µg/ml. In contrast, TGC, MER and CFX exhibited poor activity
against M. kansasii, the MIC50s and MIC90s of which were higher
than 64µg/ml.
FIGURE 2 | Cross-resistance to fluoroquinolones of Mycobacterium
kansasii isolates.
TABLE 2 | Distribution of M. kansasii classified as different subtypes.
Subtype No. of isolates (%) PCR-RFLP profiles of hsp65
BstE II fragment
lengths (bp)
Hae III fragment
lengths (bp)
I 56 (71.8) 240, 210 140, 105, 80
II 11 (14.1) 240, 135, 85 140, 105
III 8 (10.3) 240, 135, 85 140, 95, 70
IV 3 (3.8) 240, 125, 85 140, 115, 70
Distribution of Subtypes
All the 78M. kansasii isolates were genotyped by PDA method. As
shown in Table 2, they were classified as four different subtypes,
including subtype I, II, III, and IV. Of these subtypes, subtype I
was the most frequent genotype in China, accounting for 71.8%
(56/78) of M. kansasii isolates. In addition, there were 11 (14.1%),
8 (10.3%), and 3 (3.8%) isolates belonging to subtype II, III, and
IV, respectively.
Association between Subtypes and Drug
Susceptibility
We further explored the relationship between genetic subtypes
and in vitro drug susceptibility of M. kansasii, which is
summarized in Table 3. Overall, resistance to CLA was noted
in 26.8% (15/56) of subtype I isolates, while only 4.5% (1/22)
of isolates from other subtypes was resistant to CLA. Statistical
analysis revealed that the proportion of CLA-resistance among
subtype I was significantly higher than that among other subtypes
(P = 0.031). Similarly, subtype I seemed more resistant to
EMB (25.0% vs. 9.1%), MOX (33.9% vs. 9.1%), and GAT
(23.2% vs. 9.1%) than other subtypes, while the difference was
not significant (P > 0.05), which might be due to the small
sample size. In addition, our data revealed that no statistically
significant difference between subtype I and other subtypes
in the prevalence of RIF-, RFB-, LZD-, and LFX-resistance
(P > 0.05).
Frontiers in Microbiology | www.frontiersin.org 4 December 2016 | Volume 7 | Article 2097
fmicb-07-02097 December 23, 2016 Time: 17:37 # 5
Li et al. M. kansasii Subtype I and CLA Resistance in China
TABLE 3 | Percentage of drug resistance among different subtypes of
M. kansasii isolates.
Antimicrobial
agent
No. of resistant isolates (%) P-value
Subtype I (56) Subtype II, III,
and IV (22)
CLA 15 (26.8) 1 (4.5) 0.031
AMK 4 (7.1) 0 (0.0) 0.572
RIF 31 (55.4) 13 (59.1) 0.765
RFB 19 (33.9) 8 (36.4) 0.839
EMB 14 (25.0) 2 (9.1) 0.211
LZD 19 (25.0) 6 (27.3) 0.571
MOX 11 (33.9) 2 (9.1) 0.330
LFX 24 (42.9) 7 (31.8) 0.370
GAT 13 (23.2) 2 (9.1) 0.210
SUL 11 (19.6) 2 (9.1) 0.330
TABLE 4 | Minimal inhibitory concentration (MICs) of CLA and AZM and
mutations in the 23S rRNA gene in CLA-resistant M. kansasii isolates.
Mutation in
23S rRNA
MIC range of
CLA (µg/ml)
MIC range of
AZM (µg/ml)
No. of isolates
(%)
A2058T 32–128 16–128 6 (37.5)
A2058C 64–128 32–128 3 (18.8)
NA 32–128 4–128 7 (43.8)
Total 32–128 4–128 16 (100.0)
Mutations in 23S Ribosomal RNA
Conferring CLA Resistance
As shown in Table 4, the presence of mutations in 23S rRNA
was associated with 56.2% (9/16) of CLA-resistant isolates, while
7 (43.8%) of the 16 CLA-resistant isolates were found to have
no mutations at positions 2058 and 2059. A total of two types
of mutations were observed in 23S rRNA. The most frequent
mutation conferring CLA resistance was A-to-T substitution at
position 2058, and six isolates harboring this mutation showed
resistant to CLA, the MICs of which ranged from 32 to 128µg/ml.
In addition, another substitution at position 2058 (A-to-C) was
found in three CLA-resistant isolates.
DISCUSSION
To our best knowledge, the present study is the first provided
fundamental information on the drug susceptibility and
molecular analysis of M. kansasii isolates from China. In keeping
with previous reports, our results demonstrated that AMK
exhibits favorable in vitro activity against M. kansasii isolates,
which supports its important role in the initial treatment
of M. kansasii infections (van Ingen et al., 2010; Cowman
et al., 2016). Notably, we found that the prevalence of CLA-
resistance was 20.5%, which was higher than that from Spain
(0%) (Guna et al., 2005), Netherlands (1%) (van Ingen et al.,
2010), Brazil (3%) (da Silva Telles et al., 2005), and UK (13%)
(Cowman et al., 2016). Due to the satisfactory antibacterial
activity and rare adverse effect, macrolides have been used
as the first-choice treatment for respiratory tract infection
(Yezli and Li, 2012). Numerous literatures have demonstrated
that the misuse of macrolides is associated with emergency
and increased prevalence of CLA-resistant bacteria in China
(Wang et al., 1998, 2001; Chen et al., 2013), which may also
serve as a major contributor to the high prevalence of CLA-
resistant M. kansasii isolates in China. In vitro susceptibility of
non-tuberculous mycobacteria against CLA exhibits excellent
correlation with clinical outcomes (Cowman et al., 2016), the
high proportion of CLA-resistant M. kansasii in China thus
highlights the urgent need to perform in vitro CLA susceptibility
testing before the initial treatment with regimen containing
CLA.
The common in vitro resistance to LFX and RIF was observed
from our data, indicating the inclusion of these drugs in the
therapeutic regimen is controversial. However, the good activity
of MOX was detected in this study, which is consistent to
previous results from van Ingen et al (van Ingen et al., 2010).
A recent study revealed that the combination of MOX and
CLA is associated with attenuated CLA activity in a murine
model (Kohno et al., 2007). Nevertheless, MOX is an alternative
antimicrobial agent for the patients infected with CLA-resistant
M. kansasii.
Point mutations at either position 2058 or 2059 in the 23S
rRNA gene have been reported to confer macrolide resistance
phenotypes in NTM species (Inagaki et al., 2011; Zhao et al.,
2014). For M. avium complex, almost 90% of CLA-resistant
isolates harbor nucleotide substitutions in the 23S rRNA gene
(Inagaki et al., 2011). In contrast, our data revealed that more
than 40% of CLA-resistant M. kansasii isolates had no mutation
at either position 2058 or 2059 of the 23S rRNA gene. The
unsatisfactory correlation between in vitro CLA resistance and
mutations of 23S rRNA indicates that other mechanisms, such
as eﬄux pump and methylation of 23S rRNA, may be involved in
CLA resistance for M. kansasii (Inagaki et al., 2011; Brown-Elliott
et al., 2012).
Mycobacterium kansasii subtype I is the most frequent subtype
isolated from humans in many geographic areas of the world
(da Silva Telles et al., 2005). In agreement with previous reports,
the subtype I is also the predominant genotype of M. kansasii in
China, the prevalence of which is similar to that in Switzerland
(68%) (Taillard et al., 2003), although it is lower than that in
Spain (98%) (Santin et al., 2004) and Brazil (98%) (da Silva Telles
et al., 2005), and higher than that in Germany (33%) (Richter
et al., 1999), Poland (40%) (Bakula et al., 2013), and France
(43%) (Alcaide et al., 1997). Hence, the distribution of subtype
I exhibits geographical diversity, which may be associated with
the existence of different ecosystems for these microorganisms
(Taillard et al., 2003). In addition, only 14.1% of M. kansasii
isolates in this study were classified as subtype II, lower than
data from previous studies (Alcaide et al., 1997; Richter et al.,
1999). Different from Subtype I, Subtype II is considered as an
opportunistic agent, which seems to be more frequently isolated
from HIV-infected patients (Taillard et al., 2003). Thus, the low
prevalence of subtype II may be due to the low epidemic of HIV
in China.
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Another important finding of the current study is that
M. kansasii subtype I is associated with CLA resistance in
China. Subtype I is the most common cause responsible for
human infection by M. kansasii, while the other subtypes are
likely to be isolated from environmental samples (Taillard et al.,
2003). We speculate that the different drug susceptibility profiles
between subtype I and other subtypes may reflect their significant
difference in ecological niches. Due to more frequent exposure
to antibiotic selection pressure from human, subtype I emerges
the higher proportion of drug resistance to increase adaptability
in hosts. Given that CLA-based drug regimens are effective
options for treatment of M. kansasii infection, the statistical
difference observed in CLA-resistance between subtype I and
other subtypes is reasonable. In line to our hypothesis, we also
found that subtype I was more likely to be resistant to EMB,
MOX, and GAT than other subtypes. Unfortunately, because
the small sample size undermines the statistical power, the
difference was not statistically significant. Further study with
more than 200 isolates will be required to determine the potential
relationship between M. kansasii subtypes and drug susceptibility
profiles.
There were several obvious limitations in this study. First,
although chronic pulmonary disease is the most frequent clinical
manifestation of NTM infection, it also causes extrapulmonary
diseases, such as lymphatic, skin and soft tissue diseases (Griffith
et al., 2007). Considering the predominance of M. kansasii
subtype I in the pulmonary diseases from our observations, it is
important to investigate the distribution of difference subtypes in
the extrapulmonary infections due to M. kansasii. Unfortunately,
the isolates enrolled in this study were only collected from
suspected pulmonary tuberculosis patients, which impedes the
further analysis. Second, HIV status in patients, who are at a
high risk for NTM diseases (Henkle and Winthrop, 2015), was
not collected. Due to the relative low prevalence of HIV in
China, routine HIV examination is not performed among TB
patients. On the basis of our findings, future studies will be
done to validate the distribution of M. kansasii subtypes in these
special populations, which will extend our knowledge of host
preference and bacterial pathogenicity among various M. kansasii
subtypes.
CONCLUSION
Our data demonstrate that AMK is the most active agent against
M. kansasii in vitro, while the high proportion of CLA resistance
is noted in M. kansasii isolates from China. Further PRA analysis
reveals that subtype I is the predominant genotype of M. kansasii
in China. In addition, M. kansasii subtype I is associated with
CLA resistance. Given the CLA-containing regimen frequently
used in the treatment M. kansasii, the high proportion of CLA
resistance in China highlights the urgent need to perform in vitro
CLA susceptibility testing before the initial treatment with CLA.
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